NCT00783588View on ClinicalTrials.gov

A Phase I Extension Trial of Repeated Infusions of ISF35

PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions
Chronic Lymphocytic Leukemia
Interventions
BIOLOGICAL

ISF35

Subjects participating in this study will receive up to two doses of 1x10\^8, 3x10\^8, or 1x10\^9 autologous Ad-ISF35-transduced CLL B cells, depending on the dose they received in the previous Phase I trial.

Trial Locations (1)

77030

University of Texas M.D. Anderson Cancer Center, Houston

Sponsors

Lead Sponsor

Memgen, LLC
All Listed Sponsors
lead

Memgen, LLC

INDUSTRY

NCT00783588 - A Phase I Extension Trial of Repeated Infusions of ISF35 | Biotech Hunter | Biotech Hunter